BI
ITCI

BVF Inc’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

BVF Inc’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-273,350
Closed -$3.96M – 47
2017
Q4 		$3.96M Sell
273,350
-676,650
-71% -$10.4M 0.48% 36
2017
Q3 		$15M Buy
+950,000
New +$13.9M 1.91% 19

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc's ITCI Position: Q1 2018 in Review

BVF Inc sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2018, closing a stake of 273,350 shares — an estimated $3.96M sold.

BVF Inc first reported a position in ITCI in Q3 2017 and held it in 2 quarters. The position peaked at $15M in Q3 2017. 131 funds tracked by Wall St. Rank hold ITCI as of Q1 2018.

  • BVF Inc reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2018 after selling out during the quarter.
  • BVF Inc sold 273,350 Intra-Cellular Therapies Inc. shares in Q1 2018, an estimated $3.96M.
  • BVF Inc first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and held it in 2 quarters.
  • BVF Inc's Intra-Cellular Therapies Inc. position peaked at $15M in Q3 2017.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2018.

Based on BVF Inc's 13F filing for Q1 2018, filed 7 May 2018.